From: Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3
Group | Cohort A | Cohort B | ||||
---|---|---|---|---|---|---|
Control | SCA3 | Control1 | Preclinical SCA3 | Control2 | Manifest SCA3 | |
n | 9 | 17 | 21 | 26 | 70 | 90 |
Age | 54.33 ± 11.69 | 49.88 ± 11.75 | 31.62 ± 11.61 | 31.38 ± 9.30 | 43.13 ± 12.66 | 43.90 ± 12.16 |
Sex (M/F) | 4/5 | 6/11 | 8/13 | 9/17 | 31/39 | 41/49 |
Expanded CAG repeats | N/A | 73.18 ± 3.64 | N/A | 72.62 ± 4.97 | N/A | 73.91 ± 4.04 |
SARA | N/A | 13.82 ± 5.56 | N/A | 0.73 ± 0.83 | N/A | 11.72 ± 6.02 |
ICARS | N/A | 35.00 ± 11.06 | N/A | 1.81 ± 1.81 | N/A | 29.04 ± 13.90 |
Disease duration (ys) | N/A | 5.82 ± 3.56 | N/A | N/A | N/A | 6.59 ± 5.53 |
Total intracranial volume (mL) | N/A | N/A | N/A | 1416.00 ± 128.60 (n = 2) | N/A | 1496.00 ± 231.20 (n = 66) |
Cerebellum (mL) | N/A | N/A | N/A | 148.17 ± 87.77 (n = 2) | N/A | 127.07 ± 21.27 (n = 66) |
Brainstem (mL) | N/A | N/A | N/A | 22.17 ± 1.38 (n = 2) | N/A | 20.05 ± 4.66 (n = 66) |
Serum NfL (pg/mL) | 9.10 ± 3.29 | 41.50 ± 14.78 | 6.88 ± 2.72 | 15.03 ± 7.49 | 9.07 ± 6.02 | 37.56 ± 13.47 |
CSF NfL (pg/mL) | 471.70 ± 210.40 | 4262.00 ± 1762.00 | N/A | N/A | N/A | N/A |